April 5, 2016
As the interface between the laboratory and the ward, point-of-care coordinators (POCCs) perform much of their work while out in different hospital locations. This can be challenging when managing important tasks that require a PC, like performing remote troubleshooting tasks, arranging operator training, checking the status of a device or replacing an instrument. The new cobas® infinity Point-of-Care (POC) mobile now enables POCCs to complete all these tasks on a smartphone or tablet, no matter where they are – saving them valuable time and increasing their productivity.
In order to ensure that the app’s design and functionality meet the users’ needs, Roche also commissioned a study with selected customers to better understand how POCCs use IT remotely. The list of identified tasks is the core of the cobas® infinity POC mobile’s functionality. Prior to its release, the app received high scores from pilot groups of well-experienced POC specialists based on its usability and task oriented functionalities.
cobas® infinity POC mobile is available for iOS and Android devices and works in conjunction with the Roche cobas IT 1000 application. The app is another piece in the Roche “Personalized Lab Automation” portfolio, which was developed to provide quality, flexibility, efficiency and connectivity for every lab.
About cobas® IT 1000
The cobas IT 1000 solution allows for management of system configurations, test and material management, operator and Point of Care instrument management, as well as quality control and extensive reporting functions. It connects the full Roche POC portfolio including Accu-Chek Inform II, CoaguChek XS Plus and Pro, cobas h 232, cobas b 101, Urisys 1100, cobas b 121, cobas b 123, cobas b 221. Find out more at www.cobas.com.
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry seven years in a row by the Dow Jones Sustainability Indices.
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2015 employed more than 91,700 people worldwide. In 2015, Roche invested CHF 9.3 billion in R&D and posted sales of CHF 48.1 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.